Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Specific genetic target could help explain the variation in COVID-19 effects

The Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has identified a specific genetic target that could help explain the tremendous variation in how sick those infected with COVID-19 become.

17 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Pomegranate extract could inhibit the virus that causes COVID-19

Researchers have conducted a study demonstrating the potential antiviral effects of pomegranate extract against SAR-CoV-2.

3 Dec 2020

Researchers identify effective way to protect vulnerable people from COVID-19

T-cells taken from the blood of people who recovered from a COVID-19 infection can be successfully multiplied in the lab and maintain the ability to effectively target proteins that are key to the virus's function, according to a new study published Oct. 26 in Blood.

27 Oct 2020

Study shows how genetic predisposition contributes to the development of multiple sclerosis

About half of the people with multiple sclerosis have the HLA-DR15 gene variant. A study led by the University of Zurich has now shown how this genetic predisposition contributes to the development of the autoimmune disease multiple sclerosis in combination with environmental factors.

22 Oct 2020

A new therapeutic approach for Epstein-Barr virus-associated tumors

A research team at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) discovered that exosomes derived from Vδ2-T cells (Vδ2-T-Exos) can effectively control Epstein-Barr virus-associated tumours and induce T-cell anti-tumour immunity.

12 Oct 2020

Exciting findings on CD8 T cell response in recovered COVID patients

An international team of scientists has identified novel T cell-recognized epitopes spanning different proteins of severe acute respiratory syndrome coronavirus 2 in COVID-19 recovered patients. The scientists have also revealed phenotypical characteristics of the T cell population.

11 Oct 2020

Case report of arthritis in a COVID-19 patient

The current paper published in the The Lancet Rheumatology discusses arthritis in a 58-year-old white woman with COVID-19 of less than severe intensity.

7 Oct 2020

Discovery of high affinity binders for SARS-CoV-2 spike protein

An exciting, 'tour-de-force' paper by researchers from the Massachusetts Institute of Technology describes de novo discovery of high-affinity peptide binders for SARS-CoV-2 spike glycoprotein, which opens the door for the development of rapid viral identification or conjugates for virus-directed delivery of therapeutics.

30 Sep 2020

Discovering a molecule that could interfere with SARS-CoV-2 replication

In this interview, News-Medical speaks to Stepan Nersisyan about his discovery of a molecule that could replicate SARS-CoV-2.

22 Sep 2020

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

Now, a new study published on the preprint server bioRxiv* in August 2020 reports the induction of neutralizing antibodies in mice by a single dose of a ferritin nanoparticle-based vaccine containing the spike protein.

1 Sep 2020

COVID-19 could compromise key element of immune response

Researchers at the University of Melbourne have made the unsettling discovery that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might compromise the activation of the CD8+ T-cell responses that would usually ameliorate disease and drive recovery in cases of respiratory disease.

20 Aug 2020

COVID-19 virus acts as a 'sponge' to deplete specific host microRNAs

Why is the COVID-19 virus deadly, while many other coronaviruses are fairly innocuous and just cause colds?

15 Aug 2020

Kids with silent malaria remain vulnerable to developing endemic Burkitt lymphoma

A study has found strong similarities between children with endemic Burkitt lymphoma — an aggressive cancer that attacks the body's defense system and children with silent malaria infection.

10 Aug 2020

Severe fatigue common in COVID-19, independent of disease severity

Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection often complain of fatigue, but now a new study shows that it also causes severe and frequent fatigue in those who recover after mild illness too.

2 Aug 2020

EBV viral genome alters the host epigenetic landscape to drive stomach cancer

The Epstein-Barr virus (EBV), one of the most common human viruses, is associated with about 8-10 per cent of stomach -- or gastric -- cancers, the third leading cause of cancer death globally.

27 Jul 2020

Cerebrospinal fluid autoantibodies target the brain in some COVID-19 patients

A study conducted by German researchers has shown that the neurological symptoms observed in some patients with coronavirus disease 2019 (COVID-19) may be caused by autoantibodies targeting the brain.

7 Jul 2020

Well-known cancer drugs may prevent SARS-CoV-2 viral replication say researchers

Researchers in Frankfurt, Germany, have described cell signaling events that occur when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells and have identified pathways that are essential for the virus to replicate.

17 May 2020

Varied performance of SARS-CoV-2 antibody tests in detecting protective immunity

The performance of commercially available serological tests in real patient samples and the correlates of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided by IgG antibodies are still a matter of debate. A new bioRxiv preprint paper cross-examines the performance of several assays and proclaims the plaque reduction neutralization test (PRNT) as a method of choice.

11 May 2020

China with the world: COVID-19 experts dialogues - the 2nd talk transcript

Q: Starting from the patient admission to the hospital, what is your rule for ventilation? Do you start from HFNC, CPAP, NIV or go directly to intubation and invasive ventilation when the conventional oxygen therapy fails?

From Mindray 15 Apr 2020